Answers are grounded in this paper and cite their sources.
Evaluates shifts in mortality trends in hematologic and circulatory diseases, indicating significant post-pandemic increases.
The COVID-19 pandemic disrupted healthcare systems and may have influenced mortality trends in hematologic-immune disorders (D50-D89) and Diseases of the circulatory system (I00-I99). This study evaluates US mortality trends from 2010 to 2023 to assess potential pandemic-related changes. We utilized spline regression modeling on CDC WONDER mortality data (2010–2023) to quantify post-pandemic trend shifts in both age-adjusted and sex/age-stratified mortality rates. Post-2019 mortality trends for D50-D89 and I00-I99 diseases showed significant increases, particularly among older adults and younger males. D50-D89 mortality in females ≥ 65 increased ~ 2.6% (95% CI 1.70% to 3.68%) annually, while males ≥ 65 increased ~ 1.6% (95% CI 0.28% to 3.07%) annually; younger males (15–34 years) showed a 4.5% (95% CI 0.49% to 8.87%) annual increase. I00-I99 mortality increases were most pronounced in older females (~ 1.4% annual increase, 95% CI 0.49 to 2.31). Analysis of standardized rates in all groups except for men in I00–I99 showed a positive slope-shift after 2019. ( p < 0.05)”. These findings highlight the persistent impact of the COVID-19 pandemic on hematologic and circulatory system disease mortality, emphasizing the need for continued monitoring of vulnerable populations.
No takes yet. Share an insight, caveat, or question.
Bachemir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: